Repatha ® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets
New Analysis From Cardiovascular Outcomes Trial Shows Addition of Repatha in Patients Considered at Goal Further Reduces Cardiovascular Event Risk
Separate Analysis Demonstrates Consistent Cardiovascular Risk Reduction in Patients Even on Maximum-Intensity Statin Therapy
THOUSAND OAKS, Calif., May 20, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the Repatha® (evolocumab) cardiovascular outcomes trial (FOURIER), which showed that Repatha consistently and safely reduced cardiovascular events in patients with established cardiovascular disease regardless of baseline low-density lipoprotein c...
Source: Amgen News Release - May 20, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Voting Results of Annual Meeting of Stockholders
THOUSAND OAKS, Calif., May 19, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 90 percent of outstanding shares were represented at the meeting.
The director nominees David Baltimore, Robert A. Bradway, François de Carbonnel, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Frank C. Herringer, Charles M. Holley Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar and R. Sanders Williams were each re-elected to Amgen's Board of Directors. Each director received at least 95 per...
Source: Amgen News Release - May 19, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Submits Biologics License Application To The FDA For Erenumab
Erenumab is an Investigative Treatment Specifically Designed to Prevent Migraine
Only Molecule in Late-Stage Development to Directly Target the Calcitonin Gene-Related Peptide Receptor
Amgen and Novartis to Co-Commercialize Erenumab in the U.S.
THOUSAND OAKS, Calif., May 18, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for erenumab to prevent migraine. Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor. This BLA includes data from pivo...
Source: Amgen News Release - May 18, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio
Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease
XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO®
First Randomized Study to Evaluate the Combination of IMLYGIC® (talimogene laherparepvec), an Oncolytic Viral Immunotherapy, With a Checkpoint Inhibitor to be Presented
THOUSAND OAKS, Calif., May 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting ...
Source: Amgen News Release - May 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference
THOUSAND OAKS, Calif., May 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2017 Health Care Conference at 8 a.m. PT on Wednesday, May 17, 2017. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering...
Source: Amgen News Release - May 12, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha ® (Evolocumab)
Harvard Pilgrim Refines the Utilization Management Criteria to Help High-Risk Cardiovascular Patients Access Repatha
First-of-its-Kind Contract Will Demonstrate Value to Harvard Pilgrim Plans for Cardiovascular Patients
THOUSAND OAKS, Calif., May 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced from the World Medical Innovation Forum™ focused on cardiovascular disease that Harvard Pilgrim, a health services company providing healthcare coverage for nearly 2.7 million customers in the northeast region of the U.S.,1 has signed an outcomes-based refund contract with Amgen for Repatha® (evolocumab). This f...
Source: Amgen News Release - May 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Participate In The 2017 World Medical Innovation Forum ™ Focused On Cardiovascular Disease
THOUSAND OAKS, Calif., April 27, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to participate in the World Medical Innovation Forum™ focused on cardiovascular disease held May 1-3, 2017, in Boston. The World Medical Innovation Forum is a global gathering of senior corporate, investor and academic leaders. The forum was established to respond to the intensifying transformation of health care and its impact on innovation. This is the third year Amgen has participated in this event as a sponsor.
Four senior leaders from Amgen are scheduled to speak:
Robert A. Bradway, chairman and chief executive o...
Source: Amgen News Release - April 27, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Participate In The 2017 World Medical Innovation Forum ™ Focused On Cardiovascular Disease
THOUSAND OAKS, Calif., April 27, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to participate in the World Medical Innovation Forum™ focused on cardiovascular disease held May 1-3, 2017, in Boston. The World Medical Innovation Forum is a global gathering of senior corporate, investor and academic leaders. The forum was established to respond to the intensifying transformation of health care and its impact on innovation. This is the third year Amgen has participated in this event as a sponsor.
Four senior leaders from Amgen are scheduled to speak:
Robert A. Bradway, chairman and chief executi...
Source: Amgen News Release - April 27, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
